@article{harmon_new_2010,
	title = {New Drugs Stir Debate on Rules of Clinical Trials},
	issn = {0362-4331},
	url = {http://www.nytimes.com/2010/09/19/health/research/19trial.html},
	abstract = {Excerpt: "Controlled trials have for decades been considered essential for proving a drug’s value before it can go to market. But the continuing trial of the melanoma drug, {PLX}4032, has ignited an anguished debate among oncologists about whether a controlled trial that measures a drug’s impact on extending life is still the best method for evaluating hundreds of genetically targeted cancer drugs being developed."},
	journaltitle = {The New York Times},
	author = {Harmon, Amy},
	urldate = {2010-09-20},
	date = {2010-09-18},
	tags = {Cancer, Chemotherapy, Clinical Trials, Doctors, Drugs (Pharmaceuticals), Ethics, Food and Drug Administration, Medicine and Health, Melanomas, Regulation and Deregulation of Industry, Roche Holding {AG}}
}

